|
US20070244120A1
(en)
*
|
2000-08-18 |
2007-10-18 |
Jacques Dumas |
Inhibition of raf kinase using substituted heterocyclic ureas
|
|
EP2298311B1
(en)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
HUP0203895A3
(en)
|
1999-12-24 |
2004-09-28 |
Aventis Pharma Ltd West Mallin |
Substituted azaindoles and pharmaceutical compositions containing them and their use
|
|
WO2001057034A1
(en)
|
2000-02-07 |
2001-08-09 |
Bristol-Myers Squibb Co. |
3-aminopyrazole inhibitors of cyclin dependent kinases
|
|
AU2001253540A1
(en)
|
2000-04-25 |
2001-11-07 |
Bristol-Myers Squibb Company |
Use of 5-thio-, sulfinyl- and sulfonylpyrazolo(3,4-b)-pyridines as cyclin dependent kinase inhibitors
|
|
DZ3398A1
(fr)
*
|
2000-08-31 |
2002-03-07 |
Pfizer Prod Inc |
Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases
|
|
AU2002215053A1
(en)
*
|
2000-11-27 |
2002-06-24 |
Pharmacia Italia S.P.A. |
Phenylacetamido- pyrazole derivatives and their use as antitumor agents
|
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
EP2305255B1
(en)
*
|
2001-12-03 |
2012-08-22 |
Bayer HealthCare LLC |
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
|
|
US20050113283A1
(en)
*
|
2002-01-18 |
2005-05-26 |
David Solow-Cordero |
Methods of treating conditions associated with an EDG-4 receptor
|
|
DK1478358T3
(da)
|
2002-02-11 |
2013-10-07 |
Bayer Healthcare Llc |
Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
|
|
KR20030071029A
(ko)
*
|
2002-02-27 |
2003-09-03 |
주식회사 팜제니아 |
항암제 및 방사선 치료 증진제로서 유용한 조성물
|
|
US20030225089A1
(en)
*
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
|
DE10221052A1
(de)
*
|
2002-05-10 |
2003-12-04 |
Transmit Technologietransfer |
Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
|
|
WO2003097610A1
(en)
*
|
2002-05-17 |
2003-11-27 |
Pharmacia Italia S.P.A. |
Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
EP1542667B1
(en)
|
2002-07-24 |
2012-03-07 |
PTC Therapeutics, Inc. |
Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease
|
|
CA2495284A1
(en)
*
|
2002-09-05 |
2004-03-18 |
Neurosearch A/S |
Diarylurea derivatives and their use as chloride channel blockers
|
|
JP2006504725A
(ja)
|
2002-10-09 |
2006-02-09 |
ファイザー・プロダクツ・インク |
神経変性障害治療用ピラゾール化合物
|
|
UA81790C2
(uk)
|
2002-12-19 |
2008-02-11 |
Фармация Италия С.П.А. |
Заміщені піролопіразольні похідні як інгібітори кінази
|
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
|
GB0305426D0
(en)
*
|
2003-03-08 |
2003-04-16 |
Glaxo Group Ltd |
Novel compounds
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
ES2436524T3
(es)
|
2003-05-22 |
2014-01-02 |
Nerviano Medical Sciences S.R.L. |
Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
|
|
US7141568B2
(en)
|
2003-07-09 |
2006-11-28 |
Pfizer Italia S.R.L. |
Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
PL1663978T3
(pl)
|
2003-07-23 |
2008-04-30 |
Bayer Healthcare Llc |
Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
|
|
TW200526204A
(en)
|
2004-02-03 |
2005-08-16 |
Pharmacia Italia Spa |
1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
|
|
US7244757B2
(en)
*
|
2004-04-01 |
2007-07-17 |
Pfizer Inc |
Pyrazole-amine compounds for the treatment of neurodegenerative disorders
|
|
EP1609789A1
(en)
*
|
2004-06-23 |
2005-12-28 |
Eli Lilly And Company |
Ureido-pyrazole derivatives and their use as kinase inhibitors
|
|
AU2005273612B2
(en)
*
|
2004-08-12 |
2010-10-14 |
Pfizer Inc. |
Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
|
|
WO2006074025A1
(en)
|
2004-12-30 |
2006-07-13 |
Janssen Pharmaceutica N.V. |
Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
|
|
US20060183758A1
(en)
*
|
2005-02-17 |
2006-08-17 |
Cb Research And Development, Inc. |
Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
|
|
US7429800B2
(en)
*
|
2005-06-30 |
2008-09-30 |
Sabic Innovative Plastics Ip B.V. |
Molding composition and method, and molded article
|
|
JP5303271B2
(ja)
|
2005-07-19 |
2013-10-02 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
キナーゼ阻害剤として有用な１Ｈ−チエノ［２，３−ｃ］ピラゾール化合物
|
|
AR059826A1
(es)
*
|
2006-03-13 |
2008-04-30 |
Univ California |
Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
|
|
US20090118336A1
(en)
*
|
2006-05-03 |
2009-05-07 |
Laurent David |
Pyrazole derivatives and their use as pi3k inhibitors
|
|
WO2008046919A2
(en)
*
|
2006-10-21 |
2008-04-24 |
Abbott Gmbh & Co. Kg |
Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
|
|
TW200901974A
(en)
|
2007-01-16 |
2009-01-16 |
Wyeth Corp |
Compounds, compositions, and methods of making and using them
|
|
JP5675343B2
(ja)
*
|
2007-04-18 |
2015-02-25 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としての尿素誘導体
|
|
JP2010528114A
(ja)
*
|
2007-05-25 |
2010-08-19 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
脂肪酸アミド加水分解酵素のヘテロアリール置換尿素モジュレータ
|
|
EP2163541A1
(en)
*
|
2008-09-12 |
2010-03-17 |
Bayer Schering Pharma Aktiengesellschaft |
Piperazine derivatives for binding and imaging amyloid plaques and their use
|
|
AU2009310352A1
(en)
*
|
2008-10-01 |
2010-05-06 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
|
|
US8598356B2
(en)
*
|
2008-11-25 |
2013-12-03 |
Janssen Pharmaceutica Nv |
Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
|
|
US8461159B2
(en)
|
2008-11-25 |
2013-06-11 |
Jannsen Pharmaceutica BV |
Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
|
|
EP3025724B1
(en)
|
2009-05-13 |
2018-07-11 |
The University of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
WO2010141809A1
(en)
|
2009-06-05 |
2010-12-09 |
Janssen Pharmaceutica Nv |
Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
|
|
US20120083476A1
(en)
|
2009-06-05 |
2012-04-05 |
Janssen Pharmaceutica Nv |
Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
|
|
EP2528604B1
(en)
|
2010-01-29 |
2017-11-22 |
The Regents of the University of California |
Acyl piperidine inhibitors of soluble epoxide hydrolase
|
|
UA108233C2
(uk)
|
2010-05-03 |
2015-04-10 |
|
Модулятори активності гідролази амідів жирних кислот
|
|
US20130109019A1
(en)
*
|
2010-07-02 |
2013-05-02 |
Adrian E. Murillo |
Hapten conjugates for target detection
|
|
WO2012022487A1
(de)
*
|
2010-08-20 |
2012-02-23 |
Grünenthal GmbH |
Substituierte cyclische carboxamid- und harnstoff-derivate als liganden des vanilloid-rezeptors
|
|
US9266855B2
(en)
|
2010-09-27 |
2016-02-23 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
|
BR112013008527A2
(pt)
|
2010-12-17 |
2016-07-12 |
Nerviano Medical Sciences Srl |
derivados de pirazolo-quinazolina substituídos como inibidores de cinase
|
|
US9090592B2
(en)
|
2010-12-30 |
2015-07-28 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
|
NZ618795A
(en)
|
2011-05-13 |
2015-07-31 |
Array Biopharma Inc |
Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
|
|
AR087701A1
(es)
*
|
2011-08-31 |
2014-04-09 |
Japan Tobacco Inc |
Derivados de pirazol con actividad inhibidora de sglt1
|
|
WO2014078328A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
CA2891334C
(en)
|
2012-11-13 |
2021-10-19 |
Array Biopharma Inc. |
Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
|
|
WO2014078331A1
(en)
*
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
ME02990B
(me)
|
2012-11-13 |
2018-10-20 |
Array Biopharma Inc |
Jedinjenja n-pirolidinil, n'-pirazolil- uree, tiouree, guanidina i cijanoguanidina kао inhibitori trka kinaze
|
|
US9822118B2
(en)
|
2012-11-13 |
2017-11-21 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
WO2014078325A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
US9828360B2
(en)
|
2012-11-13 |
2017-11-28 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
US9981959B2
(en)
|
2012-11-13 |
2018-05-29 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
WO2014078372A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
WO2014078417A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
CA2906157C
(en)
|
2013-03-15 |
2022-05-17 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
|
JP6430483B2
(ja)
|
2013-03-15 |
2018-11-28 |
ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
化学療法の間の正常細胞の一時的な保護
|
|
WO2015161283A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
|
CN106459013B
(zh)
|
2014-05-15 |
2019-10-25 |
阵列生物制药公司 |
作为trka激酶抑制剂的化合物及其用途
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
MA56193A
(fr)
*
|
2019-06-14 |
2022-04-20 |
Ifm Due Inc |
Composés et compositions pour traiter des états associés à une activité de sting
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
TW202229268A
(zh)
*
|
2020-12-22 |
2022-08-01 |
大陸商上海拓界生物醫藥科技有限公司 |
Ｃｄｋ２抑制劑及其製備方法
|
|
JP2024502474A
(ja)
|
2021-01-08 |
2024-01-19 |
アイエフエム デュー インコーポレイテッド |
Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
|
|
CN117843563A
(zh)
*
|
2024-01-02 |
2024-04-09 |
沈阳药科大学 |
含脲片段的CDKs抑制剂衍生物及其药物组合物和应用
|